LondonIsomorphic Labs has raised $7.7 billion with no drug yet in human trials.
Its oncology and immunology programmes show positive preclinical results only, the company says.
Greenoaks and Sequoia led the $5 billion round, with Alphabet, Abu Dhabi’s MGX and Temasek returning.
Isomorphic says it is preparing its first candidates for clinical trials.
How each outlet framed it
- Zhidx leans favorable
- tallies Isomorphic's $7.7bn cumulative funding and lists its investor roster, including Greenoaks, Sequoia and a16z
Sources: Zhidx